<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Derdeyn, Colin P.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">SAMMPRIS: 30-Day Outcomes after Angioplasty and Stenting</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-14</style></pages><abstract><style  face="normal" font="default" size="100%">The Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Arterial Stenosis trial [SAMMPRIS; NCT00576693] found that treatment with aggressive medical management (AMM) was superior to AMM plus percutaneous transluminal angioplasty and stenting [Chimowitz MI et al. N Engl J Med 2011]. This article presents a detailed analysis of 30-day outcomes from the stenting arm of the SAMMPRIS trial.</style></abstract><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>